Original research articles published in Nature Medicine range from basic findings that have clear implications for disease pathogenesis and therapy to the earliest phases of human investigation. Aiming to keep Ph.D. and M.D. readers informed of a wide range of biomedical research findings, the journal publishes the latest advances in cancer biology, vascular biology, neuroscience, inflammatory disease, infectious disease and metabolic disorders, among other fields. Reviews, Perspectives and other commissioned content clarify and give context to these biomedical research advances, and the News section reports on the latest developments in drug research and development. http://feeds.nature.com/nm/rss/current Nature Publishing Group en © 2026 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. Nature Medicine © 2026 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. permissions@nature.com https://www.nature.com/uploads/product/nm/rss.gif http://feeds.nature.com/nm/rss/current https://www.nature.com/articles/s41591-026-04748-1 Nature Medicine, Published online: 28 October 2026; doi:10.1038/s41591-026-04748-1

Editorial Expression of Concern: MicroRNA-133 controls cardiac hypertrophy]]> MicroRNA-133 controls cardiac hypertrophy]]> Alessandra CarèDaniele CatalucciFederica FelicettiDésirée BonciAntonio AddarioPaolo GalloMarie-Louise BangPatrizia SegnaliniYusu GuNancy D. DaltonLeonardo EliaMichael V. G. LatronicoMorten HøydalCamillo AutoreMatteo A. RussoGerald W. Dorn IIØyvind EllingsenPilar Ruiz-LozanoKirk L. PetersonCarlo M. CroceCesare PeschleGianluigi Condorelli doi:10.1038/s41591-026-04748-1 Nature Medicine, Published online: 2026-10-28; | doi:10.1038/s41591-026-04748-1 2026-10-28 Nature Medicine 10.1038/s41591-026-04748-1 https://www.nature.com/articles/s41591-026-04748-1 https://www.nature.com/articles/s41591-026-04751-6 Nature Medicine, Published online: 27 October 2026; doi:10.1038/s41591-026-04751-6

Author Correction: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial]]> Hai-Qiang MaiQiu-Yan ChenDongping ChenChaosu HuKunyu YangJiyu WenJingao LiYing-Rui ShiFeng JinRuilian XuJianji PanShenhong QuPing LiChunhong HuYi-Chun LiuYi JiangXia HeHung-Ming WangWan-Teck LimWangjun LiaoXiaohui HeXiaozhong ChenZhigang LiuXianglin YuanQi LiXiaoyan LinShanghua JingYanju ChenYin LuChing-Yun HsiehMuh-Hwa YangChia-Jui YenJens SamolHui FengSheng YaoPatricia KeeganRui-Hua Xu doi:10.1038/s41591-026-04751-6 Nature Medicine, Published online: 2026-10-27; | doi:10.1038/s41591-026-04751-6 2026-10-27 Nature Medicine 10.1038/s41591-026-04751-6 https://www.nature.com/articles/s41591-026-04751-6 https://www.nature.com/articles/s41591-026-04718-7 Nature Medicine, Published online: 27 October 2026; doi:10.1038/s41591-026-04718-7

This Review examines the cellular, organ-level and whole-body differences between metabolically healthy and metabolically unhealthy obesity, as well as variations in response to weight loss—with the goal of improving strategies for preventing and treating obesity-related metabolic disorders.]]> Gordon I. SmithMax C. PetersenSean M. HartigSamuel Klein doi:10.1038/s41591-026-04718-7 Nature Medicine, Published online: 2026-10-27; | doi:10.1038/s41591-026-04718-7 2026-10-27 Nature Medicine 10.1038/s41591-026-04718-7 https://www.nature.com/articles/s41591-026-04718-7 https://www.nature.com/articles/s41591-026-04728-5 Nature Medicine, Published online: 27 October 2026; doi:10.1038/s41591-026-04728-5

In ALS, persistent T cell responses relate to disease outcome differently in blood than in cerebrospinal fluid, with both intrathecal antigen presentation and cytomegalovirus-specific immunity linked to worse clinical outcomes.]]> Zhenzhen ChenJannika MansikkaviitaChristina SeitzSolmaz YazdaniJoonas LehikoinenElie DeebaAnikó LovikMarton KeszeiHans GrönlundHannu LaaksovirtaFang FangPentti J. TienariCaroline IngreJohn Andersson doi:10.1038/s41591-026-04728-5 Nature Medicine, Published online: 2026-10-27; | doi:10.1038/s41591-026-04728-5 2026-10-27 Nature Medicine 10.1038/s41591-026-04728-5 https://www.nature.com/articles/s41591-026-04728-5 https://www.nature.com/articles/s41591-026-04774-z Nature Medicine, Published online: 26 October 2026; doi:10.1038/s41591-026-04774-z

Publisher Correction: Phenomic profiles and disease patterns of 1.9 million participants from Our Future Health]]> Vincent J. StraubStefania BenonisdottirGiovanni Scotti BentivoglioNeil WaryRobert CampbellAugustine KongMelinda C. Mills doi:10.1038/s41591-026-04774-z Nature Medicine, Published online: 2026-10-26; | doi:10.1038/s41591-026-04774-z 2026-10-26 Nature Medicine 10.1038/s41591-026-04774-z https://www.nature.com/articles/s41591-026-04774-z https://www.nature.com/articles/s41591-026-04776-x Nature Medicine, Published online: 26 October 2026; doi:10.1038/s41591-026-04776-x

Author Correction: Sex-specific biological aging clocks across organs and omics]]> Zhiyuan SongDerek FongNaowal Azraf RahmanMichael R. DugganQu TianJian ZengXia ZhouChunrui ZouMichael S. RafiiLi ShenPaul ThompsonEleanor M. SimonsickKeenan A. WalkerAndrew ZaleskyChristos DavatzikosPaul AisenLuigi FerrucciSusan M. ResnickJunhao Wen doi:10.1038/s41591-026-04776-x Nature Medicine, Published online: 2026-10-26; | doi:10.1038/s41591-026-04776-x 2026-10-26 Nature Medicine 10.1038/s41591-026-04776-x https://www.nature.com/articles/s41591-026-04776-x https://www.nature.com/articles/s41591-026-04775-y Nature Medicine, Published online: 26 October 2026; doi:10.1038/s41591-026-04775-y

Author Correction: Liquid biopsy for early detection of pancreatic ductal adenocarcinoma]]> Caiming XuAlessandro MannucciHaiyong HanRuben M. MunozDerek CridebringSourat DarabiYuji ToiyamaYoshinaga OkugawaGagandeep SinghMustafa RaoofJoon Oh ParkJames LinGregory IdosMichael J. DemeureErkut BorazanciDouglas B. EvansSusan TsaiEunsung JunCarlos BecerraScott A. CelinskiLaleh MelstromVincent ChungGuixin ZhangDong ShangDavid L. BartlettMitsuro KandaSong Cheol KimValsamo AnagnostouGiulia Martina CavestroJohn S. BoltonAli H. ZaidiDaniel Von HoffAjay Goel doi:10.1038/s41591-026-04775-y Nature Medicine, Published online: 2026-10-26; | doi:10.1038/s41591-026-04775-y 2026-10-26 Nature Medicine 10.1038/s41591-026-04775-y https://www.nature.com/articles/s41591-026-04775-y https://www.nature.com/articles/s41591-026-04742-7 Nature Medicine, Published online: 26 October 2026; doi:10.1038/s41591-026-04742-7

As presented at the ESMO Congress 2026: In the global phase 2 MDT-BRIDGE trial, neoadjuvant durvalumab plus chemotherapy in patients with resectable and borderline resectable non-small-cell lung cancer, followed by multidisciplinary reassessment, enabled surgery in most patients, leading to encouraging pathological complete response rates, and no additional safety concerns were reported when patients with unresectable tumors continued with chemoradiotherapy and consolidative durvalumab.]]> Martin ReckErnest NadalCarl M. GayNicolas GirardAndrea Riccardo FilippiLinda W. MartinCordula PetersenDavid A. CairnsMargarita MajemAndrea ArdizzoniRosa Alvarez AlvarezAndrew RobinsonBenoit RochArnaud BoyerIlaria AttiliMaximilian DiehnDavid KurtzUgochinyere A. EmeribeIgnacio Diaz PerezMatteo Giaj LevraDavina GaleZhou ZhuNefeli GeorgouliaJonathan Spicer doi:10.1038/s41591-026-04742-7 Nature Medicine, Published online: 2026-10-26; | doi:10.1038/s41591-026-04742-7 2026-10-26 Nature Medicine 10.1038/s41591-026-04742-7 https://www.nature.com/articles/s41591-026-04742-7